Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 12/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6911637 | 0.84 | MEP1B (0.55) | MEP1B | |
| SCHEMBL17788675 | 0.84 | MEP1B (0.71) | MEP1B | |
| SCHEMBL10331798 | 0.83 | MEP1B (0.54) | MEP1BROCK2ROCK1MEN1KMT2A | |
| SCHEMBL14558488 | 0.83 | MEP1B (0.54) | MEP1B | |
| SCHEMBL19954190 | 0.82 | MEP1B (0.51) | MEP1BROCK2ROCK1KMT2A | |
| SCHEMBL23553939 | 0.81 | ROCK2 (0.60) | MEP1BROCK2ROCK1PRKD1 | |
| SCHEMBL12176728 | 0.81 | LOXL2 (0.62) | MEP1BMEN1KMT2A | |
| SCHEMBL19954176 | 0.81 | SLC7A5 (0.57) | MEP1BHDAC8HDAC6ROCK2ROCK1 | |
| SCHEMBL21152902 | 0.80 | MAPT (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8580572 | 0.78 | PRSS1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046695-B2 | Fragment synthesis of substituted cyclic peptides | ZEALAND PHARMA A/S (DK) | 2021-06-29 | — | — | US | disclosed |
| US-9745344-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046695-B2 | Fragment synthesis of substituted cyclic peptides | VIP, NPPA, NGLY1 | MEP1B 146/4885HDAC3 4496/4885HDAC4 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.